Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 801–900 of 3,636
Bjornsson, E., Gunnarsdottir, K., Halldorsson, G. H., Sigurdsson, A., Arnadottir, G. A., Jonsson, H., Olafsdottir, E. F., Niehus, S., Kehr, B., Sveinbjörnsson, G., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.120.003029 · Cited by 23
Khan, S. U., Khan, M. U., Virani, S. S., Khan, M. S., Khan, M. Z., Rashid, M. O., Kalra, A., Alkhouli, M. A., Blaha, M. J., Blumenthal, R. S., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa093 · Cited by 34
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
“mab and the ODYSSEY OUTCOMES (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial [40,64].”
BackgroundLipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 32
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
“, 2017) and ODYSSEY OUTCOMES trial (Schwartz et al., 2018).”
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease
Belch, J. J. F., Brodmann, M., Baumgärtner, I., Binder, C. J., Casula, M., Heiß, C., Kahan, T., Parini, P., Poredoš, P., Catapano, A. L., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.022 · Cited by 28
“Almost all on a statin and 89 % were also on antiplatelet therapy.”
BackgroundBelch, J. J. F., Brodmann, M., Baumgärtner, I., Binder, C. J., Casula, M., Heiß, C., Kahan, T., Parini, P., Poredoš, P., Catapano, A. L., et al. (2021) · VASA · doi:10.1024/0301-1526/a000969 · Cited by 27
“, evolocumab and alirocumab, are highly efficacious treatments that reduce LDL-C by 60% on top of statin therapy and are associated with significant reduction in cardiovascular events in outcomes studies in very high-risk populations [55, 56].”
BackgroundMethodXu, M., Zhu, X., Wu, J., Zhang, Y., Zhao, D., Wang, X., Ding, Y., Cao, Y., Li, C., Hu, W. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02208-w · Cited by 28
Banach, M., Shekoohi, N., Mikhailidis, D. P., Lip, G. Y. H., Hernández, A. V., & Mazidi, M. (2022) · Archives of Medical Science · doi:10.5114/aoms/145970 · Cited by 36
“Recent trials with PCSK9 inhibitors suggested a significant association between combination therapy and reduced risk of ischemic stroke, and a lack of significant difference in hemorrhagic stroke between groups [32, 33].”
BackgroundInfluentialTakahashi, D., Wada, H., Ogita, M., Yasuda, K., Nishio, R., Takeuchi, M., Shitara, J., Tsuboi, S., Dohi, T., Suwa, S., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.12.014 · Cited by 27
Evaluation and management of blood lipids through a woman's life cycle
Sharma, J., McAlister, J., Aggarwal, N. R., Wei, J., Mehta, P. K., Quesada, O., Mattina, D. J., Scott, N. S., Michos, E. D., Mahmoud, Z., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100333 · Cited by 35
“In the FOURIER and ODYSSEY OUTCOMES studies, the benefits of evolocumab and alirocumab were examined, respectively; women represented only approximately 25% of patients in both trials [91,92].”
MethodZhang, Y., Suo, Y., Yang, L., Zhang, X., Yu, Q., Zeng, M., Zhang, W., Jiang, X., & Wang, Y. (2022) · Cardiology Research and Practice · doi:10.1155/2022/8729003 · Cited by 27
Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor
Smith, G. A., Padmanabhan, A., Lau, B. H., Pampana, A., Li, L., Lee, C. Y., Pelonero, A., Nishino, T., Sadagopan, N., Xia, V. Q., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj8670 · Cited by 23
Sakuma, M., Iimuro, S., Shinozaki, T., Kimura, T., Nakagawa, Y., Ozaki, Y., Iwata, H., Miyauchi, K., Daida, H., Suwa, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02633-5 · Cited by 28
“Clinical implications PCSK9 inhibitors, when added to a statin, can achieve an LDL-C level as near to zero as possible [17, 18].”
BackgroundPeng, K., Li, X., Wang, Z., Li, M., & Yang, Y. (2022) · Medicine · doi:10.1097/md.0000000000032003 · Cited by 30
Ma, M., Hou, C. J., & Liu, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1148486 · Cited by 26
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
Chang, Y., Eom, S., Kim, M.-J., & Song, T. (2023) · Medicina · doi:10.3390/medicina59040776 · Cited by 31
“Adverse effects were similar among treatment groups [70].”
BackgroundBrown, R., Welsh, P. I., & Logue, J. (2020) · Open Heart · doi:10.1136/openhrt-2020-001396 · Cited by 26
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
Rivera, F. B., Cha, S. W., Linnaeus Louisse, C., Carado, G. P., Magalong, J. V., Tang, V. A., Enriquez, M. G., Gulati, M., Enkhmaa, B., Pagidipati, N., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2024.101549 · Cited by 25
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
McClintick, D. J., O’Donoghue, M. L., Ferrari, G. M. D., Ferreira, J., Ran, X., Im, K., López, J. A. G., Elliott‐Davey, M., Wang, B., Monsalvo, M. L., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.11.029 · Cited by 26
Zimerman, A., Wiviott, S. D., Park, J., Murphy, S. A., Ran, X., Bramson, C., Curto, M., Ramos, V., Jevne, A., Kuder, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae090 · Cited by 29
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 29
“…treatment decreased LDL-C by 63% and was associated with a 15% reduction in the risk of the primary endpoint—composed of death from coronary heart disease, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization—after a median follow-up of 2.8 years [34].”
BackgroundInfluentialVerma, S., Leiter, L. A., Teoh, H., Mancini, G. B. J., Quan, A., Elituv, R., Verma, M., Misner, E., Szarek, M. J., Thorpe, K. E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01633-2 · Cited by 26
Self-citationCurrent pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 26
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
Warden, B. A., Miles, J., Oleaga, C., Ganda, O. P., Duell, P. B., Purnell, J. Q., Shapiro, M. D., & Fazio, S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100012 · Cited by 25
Singh, M., McEvoy, J. W., Khan, S. U., Wood, D., Graham, I. M., Blumenthal, R. S., Mishra, A., & Michos, E. D. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.011 · Cited by 32
Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering
Agarwala, A., & Goldberg, A. C. (2020) · Future Cardiology · doi:10.2217/fca-2020-0016 · Cited by 28
Klooster, C. C. V. ’., Bhatt, D. L., Steg, P. G., Massaro, J. M., Dorresteijn, J. A. N., Westerink, J., Ruigrok, Y. M., de Borst, G. J., Asselbergs, F. W., van der Graaf, Y., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.09.053 · Cited by 26
Self-citationNakamura, M., Ako, J., Arai, H., Hirayama, A., Nohara, A., Murakami, Y., Ozaki, A., & Harada‐Shiba, M. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.59543 · Cited by 26
Alings, M., Descamps, O. S., Guillon, B., Leósdóttir, M., Maggioni, A. P., Recasens, L., Speidl, W. S., Tripodi, R., Landmesser, U., Catapano, A. L., et al. (2020) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2021.01.010 · Cited by 27
Sarak, B., Savu, A., Kaul, P., McAlister, F. A., Welsh, R. C., Yan, A. T.-K., & Goodman, S. G. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006646 · Cited by 25
Self-citationThe effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis
Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 28
Ito, M., Hiwasa, T., Oshima, Y., Yajima, S., Suzuki, T., Nanami, T., Sumazaki, M., Shiratori, F., Funahashi, K., Li, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708039 · Cited by 25
Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage
Shoamanesh, A., & Selim, M. H. (2022) · Stroke · doi:10.1161/strokeaha.122.036889 · Cited by 28
SAMSON and the Nocebo Effect: Management of Statin Intolerance
Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25
Dyslipidemia in Transplant Patients: Which Therapy?
Iannuzzo, G., Cuomo, G., Lorenzo, A. D., Tripaldella, M., Mallardo, V., Idelson, P. I., Sagnelli, C., Sica, A., Creta, M., Baltar, J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144080 · Cited by 33
Yang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 30
Costanzo, A. D., Indolfi, C., Sorrentino, S., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411739 · Cited by 25
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
“…Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab (ODYSSEY OUTCOMES) trial found a reduction in the composite outcome of coronary death, MI, stroke, and hospitalization for UA with alirocumab (9.5% vs. 11.1%, HR 0.85, 95% CI 0.78 to 0.93, NNT 63) [42] (Table 4).”
BackgroundInfluentialDixon, D. L., Pamulapati, L. G., Bucheit, J. D., Sisson, E. M., Smith, S. R., Kim, C. J., Wohlford, G. F., & Pozen, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0778-6 · Cited by 26
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
Sabouret, P. F., Galati, G., Angoulvant, D., Андреевна, Г. О., Castelletti, S., Pathak, A., Metra, M., & Margonato, A. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa051 · Cited by 24
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 26
Diseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07310-y · Cited by 23
Palacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. D. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.027 · Cited by 29
Vijayaraghavan, K., Baum, S. J., Desai, N. R., & Voyce, S. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1308173 · Cited by 26
“…cholesterol levels below target level Low-density lipoprotein cholesterol has remained the chief therapeutic target, including among statin add-on agents (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid), with the goal of reducing LDL-C levels further to lower residual risk (19 – 21 , 26).”
BackgroundLiu, Y., Lu, K., Zhang, R., Hu, D., Yang, Z., Zeng, J., & Cai, W. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00574 · Cited by 29
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
Zimerman, A., O’Donoghue, M. L., Ran, X., Im, K., Ott, B. R., Mach, F., Zavitz, K. H., Kurtz, C. E., Monsalvo, M. L., Wang, B., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400112 · Cited by 30
Faggiano, A., Gualeni, A., Barbieri, L., Mureddu, G. F., Venturini, E., Giallauria, F., Ambrosetti, M., Ruzzolini, M., Maranta, F., Silverii, M. V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020493 · Cited by 31
Mauriello, A., Correra, A., Maratea, A. C., Caturano, A., Liccardo, B., Perrone, M. A., Giordano, A., Nigro, G., D’Andrea, A., & Russo, V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051652 · Cited by 31
Marston, N., Bohula, E. A., Bhatia, A. K., Ferrari, G. M. D., Leiter, L., Nicolau, J. C., Park, J., Murphy, S. A., Walsh, E., Liu, L., et al. (2026) · JAMA · doi:10.1001/jama.2026.3277 · Cited by 30
Szarek, M. J., Steg, P. G., DiCenso, D., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Gotcheva, N. N., Jukema, J. W., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.005858 · Cited by 23
Self-citationVlachopoulos, C. V., Koutagiar, I. P., Skoumas, I., et al. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.09.024 · Cited by 23
Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Vecchio, L. D., Nicola, L. D., Leoncini, G., Mallamaci, F., Zoccali, C., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00707-2 · Cited by 30
Emerging lipid lowering agents targeting LDL cholesterol
Wójcik, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1751422 · Cited by 23
Cordero, A., Rodríguez‐Mañero, M., Bertomeu‐González, V., García‐Acuña, J. M., Baluja, A., Agra-Bermejo, R., Álvarez, B. Á., Cid, B., Zuazola, P., & González‐Juanatey, J. R. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.03.020 · Cited by 23
Kim, H. I., Ye, B., Gosalia, N., Köroğlu, Ç., Hanson, R. L., Hsueh, W., Knowler, W. C., Baier, L. J., Bogardus, C., Shuldiner, A. R., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.06.009 · Cited by 22
Li, C., Chen, Q., Zhang, M., Liu, Y., Chu, Y., Meng, F., Wang, J., Tang, J. T., Luo, J., Niu, X., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-01861-6 · Cited by 24
LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis
Masson, W. M., Lobo, M., Siniawski, D. A., Masson, G., Cobo, A. L., & Molinero, G. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105655 · Cited by 23
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Ko, S. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.4.244 · Cited by 23
Chen, P.-S., Lee, M., Tang, S., Huang, P., Yeh, H., Hou, C. J., Hsieh, C., Lee, J., Jeng, J., & Li, Y. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.03.001 · Cited by 24
Manejo do risco cardiovascular: dislipidemia
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-19 · Cited by 33
Ennezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 25
Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
Morotti, A., Barale, C., Melchionda, E., & Russo, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911446 · Cited by 26
“reduction of circulating LDL levels, ranging from 50–60% [213,214] and, importantly, a reduction of about 15% in the risk for major adverse cardiovascular events (MACE) (death from CV causes, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) [210,211], thereby indicatin…”
BackgroundNew Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
Kim, K. A., & Park, H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.37 · Cited by 23
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 30
“Several pro-protein convertase subtilisin/kexin type 9 (PCSK9) mAbs, including evolocumab and alirocumab, are now licensed for use in clinics [14, 15].”
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
Szarek, M. J., Bhatt, D. L., Miller, M. J., Brinton, E. A., Jacobson, T. A., Tardif, J., Ballantyne, C. M., Mason, R. P., Ketchum, S. B., Pineda, A. L., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.016 · Cited by 26
Self-citationMa, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23
“More recently, the CV outcome studies with the monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) have shown that very intensive lowering of LDL-C with these agents in addition to high-dose statin therapy can further reduce ASCVD events [7,8].”
BackgroundCastilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Rico, M. Á. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0563-4 · Cited by 24
Salvatore, T., Morganti, R., Marchioli, R., & Caterina, R. D. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.06.029 · Cited by 27
Management of Lipid Abnormalities in Patients with Diabetes
Sillars, A., & Sattar, N. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1246-1 · Cited by 24
Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease
Dopheide, J. F., Veit, J., Ramadani, H., Adam, L., Papac, L., Vonbank, A., Kaspar, M., Rastan, A., Baumgärtner, I., & Drexel, H. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz081 · Cited by 23
Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
Rymer, J. A., Mues, K. E., Monda, K. L., Bratton, E. W., Wirtz, H. S., Okerson, T., Overman, R. A., Brookhart, M. A., Muntner, P., & Wang, T. Y. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014347 · Cited by 23
Hollstein, T., Kassner, U., Grenkowitz, T., Schumann, F., Bobbert, T., & Steinhagen‐Thiessen, E. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00411-3 · Cited by 25
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Bonaca, M. P., George, R. T., Morrow, D. A., Bergmark, B. A., Park, J., Abuhatzira, L., Vavere, A. L., Karathanasis, S. K., Jin, C., She, D., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab001 · Cited by 22
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
A Pound of Prevention? Assessing the Value of New Cholesterol-Lowering Drugs
Hlatky, M. A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-3632 · Cited by 22
Song, C., Qiao, Z., Chen, L., Ge, J., Zhang, R., Yuan, S., Bian, X., Wang, C., Liu, Q., Jia, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879657 · Cited by 27
“However, a substantial number of patients still suffer from adverse cardiovascular events despite the reduction of LDL–c level to 40 mg/dl or less (30, 31), suggesting additional “residual cardiovascular risks” are yet to be explored.”
BackgroundGiubilato, S., Lucà, F., Abrignani, M. G., Gatto, L., Rao, C. M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185989 · Cited by 33
“Even in the most recent studies that introduced the proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in the clinical arena, the occurrence of subsequent events in the treated arms remained around 9%, despite the drastic LDL cholesterol (LDL-C) reductions [16,17].”
BackgroundPreventing new-onset heart failure: Intervening at stage A
Upadhya, B., Hegde, S., Tannu, M., Stacey, R. B., Kalogeropoulos, A. P., & Schocken, D. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100609 · Cited by 27
“Additionally, there was no effect of PCSK9 inhibitor treatment on HF hospitalization in the subgroup of HF patients in the ODYSSEY OUTCOMES study (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) [125].”
BackgroundEffects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease
Wright, R. S., Ray, K. K., Landmesser, U., Koenig, W., Raal, F. J., Leiter, L. A., Conde, L. G., Han, J., & Schwartz, G. G. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.025 · Cited by 25
Self-citationAtherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea
Nguyen, P. K. P., Zhao, D. H., Okamura, T., Kim, H. C., Wong, N. D., & Yang, E. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.006 · Cited by 30
Han, D., Tzolos, E., Park, R. H., Gransar, H., Hyun, M. C., Friedman, J. D., Hayes, S. W., Thomson, L., Kwan, A. C., Budoff, M. J., et al. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.01.005 · Cited by 29
Wiegman, A., Peterson, A. L. H., Hegele, R. A., Bruckert, É., Schweizer, A., Lesogor, A., Wang, Y., & Defesche, J. C. (2025) · Circulation · doi:10.1161/circulationaha.124.073233 · Cited by 28
Colesterol LDL, cuanto más bajo mejor
Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.003 · Cited by 29
Nesti, L., Mengozzi, A., & Natali, A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00391-z · Cited by 27
“Nevertheless, recent data from the ODYSSEY OUTCOMES study [24] with alirocumab confirmed the lower-thanexpected efficacy of extreme LDL-C lowering (from 90 to 50 mg/dl [from 2.”
ResultKim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 23
Iannuzzo, G., Gentile, M., Bresciani, A., Mallardo, V., Lorenzo, A. D., Merone, P., Cuomo, G., Pacileo, M., Sarullo, F. M., Venturini, E., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071510 · Cited by 27
Puri, R., Mehta, V., Duell, P. B., Iyengar, S. S., Yusuf, J., Dalal, J., Narasingan, S. N., Kalra, D. K., Kapoor, A., Pradhan, A. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.008 · Cited by 24
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 23
Role of Lipid-Lowering Therapy in Peripheral Artery Disease
Belur, A. D., Shah, A. J., Virani, S. S., Vorla, M., & Kalra, D. K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164872 · Cited by 28
“Schwartz (ODYSSEY OUTCOMES), 2018, 2020 [61,62] RCT 18,924 History of ACS in last 12 months, LDL-C ≥70 mg/dL, HDL-C at least 100 mg/dL, apoB at least 80 mg/dL on high-intensity or maximally tolerated dose of statin Alirocumab vs.”
BackgroundGuidelines for the management of hyperlipidemia: How can clinicians effectively implement them?
Dembowski, E., Freedman, I. G., Grundy, S. M., & Stone, N. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.009 · Cited by 25
Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy
Rosendael, S. E. V., van den Hoogen, I. J., Lin, F. Y.-H., Andreini, D., Al-Mallah, M. H., Budoff, M. J., Cademartiri, F., Chinnaiyan, K. M., Choi, J. H., Conte, E., et al. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2022.10.017 · Cited by 29
Virani, S. S., Aspry, K. E., Dixon, D. L., Ferdinand, K. C., Heidenreich, P. A., Jackson, E. J., Jacobson, T. A., McAlister, J. L., Neff, D., Gulati, M., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100472 · Cited by 27
Silverio, A., Cancro, F. P., Esposito, L., Bellino, M., D’Elia, D., Verdoia, M., Vassallo, M. G., Ciccarelli, M., Vecchione, C., Galasso, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062161 · Cited by 32
“The issue of “residual cholesterol risk” has been partially addressed with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors that dramatically reduce LDL-c levels when added to statin therapy, showing a significant reduction in cardiovascular events in patients with CAD [41,42].”
BackgroundPark, C. S., Yang, H., Han, K., Lee, H., Kang, J., Han, J., Park, K. W., Kang, H., Koo, B., & Kim, H.-S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.05.003 · Cited by 25
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

